{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/69cbcfb74bc3c0b5cea89f0c/6a4ba5b45b22488bcdc3589f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial: Original Research","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/69cbcfb74bc3c0b5cea89f0c/1783342463131-cead484f-cb88-4806-a73e-e087346b48a9.jpeg?height=200","description":"<p>In this episode of Editor's Choice, Dr Aaysha Cader speaks with Professor Huimin Chu about LAAC with AnchorMan versus Watchman 2.5 devices.</p><p><br></p><p>They discuss how the 12-month results of the SAFE-PROTECT trial indicated the non-inferiority of the novel AnchorMan occluder for both primary and secondary endpoints: clinical success and LAA closure success at 1 year. This study found that the AnchorMan’s design, intended to improve sealing, resulted in significantly lower peridevice leak ≥3 mm compared to Watchman 2.5.</p>","author_name":"EuroIntervention"}